Feinstein Max A, Lee Jun H, Amoozgar Behzad, Liu Kelsey, Stewart Jay M, Lazcano-Gomez Gabriel, Porco Travis, Han Ying
Department of Ophthalmology, San Francisco School of Medicine, University of California, San Francisco, California.
Department of Ophthalmology, Division of Glaucoma, Asociacion para Evitar la Ceguera en Mexico, Mexico City, Mexico.
Clin Exp Ophthalmol. 2019 Aug;47(6):766-773. doi: 10.1111/ceo.13501. Epub 2019 May 9.
This is the first study to compare the efficacy and safety of endocyclophotocoagulation (ECP) via pars plana (ECP-plus) with ECP via limbus (anterior ECP) for treating glaucoma.
There is no direct comparison of treatment outcomes between ECP-plus and anterior ECP.
Retrospective study.
Fifty-four consecutive patients.
Fifty-eight eyes from 54 consecutive patients underwent anterior ECP (33 eyes) or ECP-plus (25 eyes) with 2-year follow-up. Linear mixed model was used to analyse the surgical outcomes.
Intraocular Pressure (IOP) was the primary outcome. Secondary outcomes were best-corrected visual acuity, number of glaucoma medications, complications and success rate.
Compared to anterior ECP, patients in the ECP-plus group had lower IOP (estimate of effect size [EES] = -3.7 mmHg, P = 0.023) and used fewer number of glaucoma medications (EES = -1.11, P = 0.003), after adjusting for degrees of treatment, preoperative IOP, and presence of combined ECP and phacoemulsification procedure. Patients with ECP-plus achieved a higher success rate at 2 years postoperatively (80% vs 33.3%, P < 0.001). The decrease in IOP between the preoperative and last follow-up visit was greater in the ECP-plus group compared to the anterior ECP group (14.3 mmHg (52%) vs 5.2 mmHg (24%), P = 0.001). There was no significant difference in complication rates between the two groups (28% vs 33%, P = 0.561).
Anterior ECP and ECP-plus have a similar safety profile, and ECP-plus may offer superior IOP control for the management of glaucoma.
这是第一项比较经睫状体扁平部进行内循环光凝术(ECP-plus)与经角膜缘进行内循环光凝术(前ECP)治疗青光眼的疗效和安全性的研究。
ECP-plus和前ECP之间尚未对治疗结果进行直接比较。
回顾性研究。
54例连续患者。
54例连续患者的58只眼睛接受了前ECP(33只眼)或ECP-plus(25只眼)治疗,并进行了2年随访。采用线性混合模型分析手术结果。
眼压(IOP)是主要观察指标。次要观察指标包括最佳矫正视力、青光眼药物使用数量、并发症和成功率。
与前ECP相比,在调整治疗程度、术前眼压以及是否联合ECP和白内障超声乳化手术等因素后,ECP-plus组患者的眼压更低(效应量估计值[EES]=-3.7 mmHg,P=0.023),且使用的青光眼药物数量更少(EES=-1.11,P=0.003)。ECP-plus组患者术后2年的成功率更高(80%对33.3%,P<0.001)。与前ECP组相比,ECP-plus组术前至最后一次随访时眼压的降低幅度更大(14.3 mmHg(52%)对5.2 mmHg(24%),P=0.001)。两组并发症发生率无显著差异(28%对33%,P=0.561)。
前ECP和ECP-plus具有相似的安全性,且ECP-plus在控制青光眼眼压方面可能更具优势。